Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020

Gilabert, Marine; Ries, Pauline; Chanez, Brice; Triby, Simon; François, Ετιεννε; Lièvre, Astrid; Rousseau, Frédérique

doi:10.1016/j.jgo.2020.04.004

Cited by 5 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the results of other French cancer registries, our study showed an important increase in palliative chemotherapy in patients over 80 years old (18.91% versus 7.3%) over time [ 26 ]. These results are consistent with previous studies that showed that due to age and comorbidities, only a small and highly selected proportion of the elderly population received a full dose of treatment [ 27 , 28 , 29 ].…”

Section: Discussionsupporting

confidence: 93%

Predictors of Survival in Elderly Patients with Metastatic Colon Cancer: A Population-Based Cohort Study

Badic

Bouvier

et al. 2022

Cancers

View full text Add to dashboard Cite

Oncological strategies in the elderly population are debated. The objective of this study was to determine the predictive factors of survival in patients aged 80 years and older with metastatic colon cancer. Data from four digestive tumour registry databases were used in this analysis. This population-based retrospective study included 1115 patients aged 80 years and older with stage IV colon adenocarcinoma diagnosed between 2007 and 2016. Cox regression was used to assess the impact of different prognostic factors. Age was significantly correlated with the surgical treatment (p < 0.001) but not with overall survival. Patients with a low comorbidity burden had better survival than patients with higher comorbidities scores (9.4 (0–123) versus 7.9 (0–115) months) (p = 0.03). Surgery was more common for proximal colon cancer (p < 0.001), but the location of the primary lesion was not correlated with improved survival (p = 0.07). Patients with lung metastases had a better prognosis than those with liver metastases (HR 0.56 95% CI 0.40, 0.77 p < 0.001); multiple organ involvement had the worst survival (HR 1.32 95% CI 1.15, 1.51 p < 0.001). Chemotherapy was associated with improved survival for both operated (HR 0.45 95% CI 0.35, 0.58 p < 0.001) and non-operated patients (HR 0.41 95% CI 0.34, 0.50 p < 0.001). The majority of patients receiving adjuvant treatment had a low comorbidity burden. In our study, the location of metastases but not the primary tumor location had an impact on overall survival. Low comorbidity burden, curative surgery, and chemotherapy had a significant advantage for elderly patients with metastatic colon cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Predictors of Survival in Elderly Patients with Metastatic Colon Cancer: A Population-Based Cohort Study

Badic

Bouvier

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Although no large phase III studies have specifically examined the use of MoAb in older adults, post hoc subgroup analyses of several large phase III studies have shown similar efficacy between young and old patients. 9 In a German cohort study of more than 300 older adults with colorectal cancer, treatment with cetuximab combined with chemotherapy had similar objective response rate (ORR), median PFS and overall survival (OS), and incidence of rash between older and younger patients. 10 Some small studies have also explored the use of anti-EGFR monotherapy in frail populations deemed unfit for chemotherapy (based on performance status [PS] or physician's judgment) with modest efficacy results in responses, median PFS and OS, but good tolerability including rash in 15.2%-16.7% of patients.…”

Section: Antiepidermal Growth Factor Receptor Moabmentioning

confidence: 99%